可溶性尿激酶型纤溶酶原激活物受体在肾脏病中的研究进展

Research progress of soluble urokinase-type plasminogen activator receptor in kidney diseases

可溶性尿激酶型纤溶酶原激活物受体(suPAR)是尿激酶型纤溶酶原激活物系统的组成部分,是尿激酶型纤溶酶原激活物受体(u PAR)的可溶形式,作为一种新的诊断生物标志物,在各种炎性疾病、心脑血管疾病、亚临床器官损害、自身免疫性疾病及肿瘤等多种疾病的发生发展及预后评估中发挥重要作用。近年来国内外研究发现suPAR与多种肾脏疾病有关。该文主要阐述了suPAR的结构、功能,与肾疾病的发生机制以及对suPAR在原发性肾病综合征、糖尿病肾病、IgA肾病、慢性肾脏病、APOL1风险变异、急性肾损伤等多种肾脏病中的研究进展进行综述。

Soluble urokinase-type plasminogen activator receptor(suPAR)is a component of the urokinase-type plasminogen activator system,and it is a soluble form of urokinase-type plasminogen activator receptor(uPAR).As a new diagnostic biomarker,it plays an important role in the occurrence,development and prognosis evaluation of various diseases such as various inflammatory diseases,cardiovascular and cerebrovascular diseases,subclinical organ damage,autoimmune diseases and tumors.Recent studies at home and abroad have found that suPAR is associated with a variety of kidney diseases.This article mainly explains the structure and function of suPAR and the pathogenesis of renal disease.It also reviews the research progress of suPAR in a variety of kidney diseases such as primary nephrotic syndrome,diabetic nephropathy,IgA nephropathy,chronic kidney disease,APOL1 risk variation,and acute kidney injury.